ClinicalTrials.gg
Active, not recruitingNCT04544436MUSETTEUpdated Nov 10, 2026Results posted

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

A Phase 3 interventional study of Ocrelizumab and Ocrelizumab in Multiple Sclerosis, sponsored by Hoffmann-La Roche. Active, not recruiting at 121 sites in 21 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Nov 10, 2026Study completion moved2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
864
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
3rd of 27
864 · median 170
Started
2020
with 4 others
Phase 3
13 of 27
2 open now
Primary completion
2024-12
later than 2 of 13 live
Registered
13th of 27
by date
Lead sponsor
13 of 27
Hoffmann-La Roche

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 3rd largest by enrollment, is one of 5 that started in 2020, is one of 13 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 13th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.

Read the detailed description

Participants will be treated for a minimum of 120 weeks in the double-blind treatment (DBT) phase. Upon positive primary results after the DBT phase, an optional higher dose extension treatment, open-label extension (OLE) phase is planned for eligible participants. The OLE will be carried out for approximately 96 weeks. Participants will be followed for safety for 48 weeks thereafter. Participants whose B-cell levels still did not replete to their baseline level or the low level of normal (LLN), whichever is lower, will move into the B-cell monitoring (BCM) phase following the safety follow-up phase. The study will end when all participants who were not treated with an alternative B-cell depleting therapy have repleted their B-cells to the baseline value or the LLN.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Relapsing Remitting Multiple Sclerosis; Higher Dose of CD20 Antibody Ocrelizumab; Efficacy, Safety and Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RMS
  • At least two documented clinical relapses within the last 2 years prior to screening, or one clinical relapse in the year prior to screening. No relapse 30 days prior to screening and at baseline
  • Participants must be neurologically stable for at least 30 days prior to randomization and baseline
  • EDSS score, at screening and baseline, from 0 to 5.5 inclusive
  • Average T25FWT score over two trials at screening and over two trials at baseline respectively, up to 150 (inclusive) seconds
  • Average 9HPT score over four trials at screening and over four trials at baseline respectively, up to 250 (inclusive) seconds
  • Documented magnetic resonance imaging (MRI) of brain with abnormalities consistent with MS at screening
  • Participants requiring symptomatic treatment for MS and/or physiotherapy must be treated at a stable dose. No initiation of symptomatic treatment for MS or physiotherapy within 4 weeks of randomization
  • Females of , agreement to remain abstinent or use adequate methods
  • Female participants without may be enrolled e.g. if or if surgically sterile

Exclusion criteria

Exclusion Criteria:

  • History of primary progressive MS at screening
  • Any known or suspected active infection at screening or baseline (except nailbed infections), or any major episode of infection requiring hospitalization or treatment with IV antimicrobials within 8 weeks or treatment with oral antimicrobials within 2 weeks, prior to and during screening
  • History of confirmed or suspected progressive multifocal leukoencephalopathy
  • History of cancer, including hematologic and solid tumors, within 10 years of screening
  • state
  • Receipt of a live or within 6 weeks prior to randomization
  • Inability to complete an MRI or to gadolinium administration
  • Contraindications to mandatory pre-medications for infusion-related reaction (IRRs)
  • Known presence of other neurologic disorders that could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
  • Any concomitant disease that may require chronic treatment with systemic or immunosuppressants during the course of the study
  • Significant, uncontrolled disease that may preclude participant from participating in the study
  • History of or currently active primary or secondary, non-drug-related, immunodeficiency
  • Pregnant or breastfeeding or intending to become pregnant
  • Lack of peripheral venous access
  • History of alcohol or other drug abuse within 12 months prior to screening
  • Treatment with any agent within 24 weeks prior to screening or treatment with any experimental procedure for MS
  • Previous use of anti- cluster of differentiation 20 (CD20s) (including ocrelizumab), unless the last infusion was more than 2 years before screening, B-cell count is normal, and the stop of the treatment was not motivated by safety reasons or lack of efficacy
  • Previous treatment with fingolimod, siponimod, or ozanimod within 6 weeks of baseline
  • Previous treatment with natalizumab within 4.5 months of baseline
  • Previous treatment with interferons beta (1a or 1b), or glatiramer acetate within 2 weeks of baseline
  • Any previous treatment with mitoxantrone, cladribine, atacicept, alemtuzumab, and daclizumab - Previous treatment with any other immunomodulatory or immunosuppressive medication not already listed above without appropriate as described in the applicable local label. If the washout requirements are not described in the applicable local label, then the wash out period must be five times the half-life of the medication
  • Any previous treatment with bone marrow transplantation and hematopoietic stem cell transplantation
  • Any previous history of transplantation or anti-rejection therapy
  • Treatment with IV immunoglobulin (Ig) or plasmapheresis within 12 weeks prior to randomization
  • Systemic corticosteroid therapy within 4 weeks prior to screening
  • Positive screening tests for active, latent, or inadequately treated
  • Sensitivity or intolerance to any ingredient (including ) of ocrelizumab
  • Any additional exclusionary criterion as per ocrelizumab local label, if more stringent than the above
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
864 participants (actual)

Study arms

  • Experimental
    Ocrelizumab Higher Dose

    Participants will be randomized to receive a minimum of 5 higher treatment doses based on their body weight at baseline: 1200 mg (participant's body weight \<75 kilograms \[kg\]) or 1800 mg (participant's body weight ≥ 75 kg) of ocrelizumab administered by IV infusion Q24W in the DBT phase. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.

    Drug: Ocrelizumab · Drug: Antihistamine · Drug: Methylprednisolone

  • Active comparator
    Ocrelizumab Approved Dose

    Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by IV infusion Q24W in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.

    Drug: Ocrelizumab · Drug: Antihistamine · Drug: Methylprednisolone

Interventions

  • The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total).

    Also known as: Ocrevus

  • Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.

    Also known as: Ocrevus

  • Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.

    Also known as: Non-Investigational Medicinal Product

  • Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.

    Also known as: Non-Investigation Medicinal Product

06

What researchers measure

Primary outcomes

  1. Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)

    Time to onset of 12-week cCDP=first occurrence of a 12-week cCDP according to at least 1 of the 3 criteria: 1) CDP=12-week confirmed increase (CI) from baseline (FB) in expanded disability status scale (EDSS) score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 12-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 12-week CI of ≥20% FB in Timed 25-foot Walk Test (T25FWT) score OR 3)12-week CI of ≥ 20% FB in 9-hole Peg Test (9-HPT) score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Time to Onset of 24-week cCDP (cCDP24)

    Time to onset of a 24 week cCDP=first occurrence of a 24-week cCDP according to at least 1 of 3 criteria: 1) CDP=24-week CI from baseline in EDSS score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 24-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 24-week CI of ≥20% FB in T25FWT score OR 3) 24-week CI of ≥ 20% FB in 9-HPT score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

    Time frame: Up to approximately 4 years

  2. Time to Onset of 48-week cCDP (cCDP48)

    Time to onset of a 48-week cCDP=first occurrence of a 48-week cCDP according to at least 1 of 3 criteria: 1) CDP=48-week CI from baseline in EDSS score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 48-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 48-week CI of ≥20% FB in T25FWT score OR 3) 48-week CI of ≥ 20% FB in 9-HPT score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

    Time frame: Up to approximately 4 years

  3. Time to Onset of cCDP12 Independent of Protocol-defined Relapses (PDR) or Progression Independent of Relapse Activity (PIRA)

    Time to onset of 12-week cCDP=first occurrence of a 12-week cCDP according to at least 1 of 3 criteria: 1) CDP=12-week CI from baseline in EDSS score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 12-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 12-week CI of ≥20% FB in T25FWT score OR 3) 12-week CI of ≥ 20% FB in 9-HPT score. EDSS score, T25FWT \& 9-HPT are the same as defined in primary outcome measure. Protocol-defined relapse=occurrence of new or worsening neurological symptoms attributable to MS and immediately preceded by a relatively stable or improving neurological state of at least 30 days. Symptoms persist for at least 24 hours \& accompanied by objective neurological worsening consistent with an increase of one of the following: Half a step (0.5 point) on the EDSS; Two points on one of the functional system scores (FSS) (pyramidal, ambulation, cerebellar, brainstem, sensory, or visual); One point on ≥2 more of the FSS.

    Time frame: Up to approximately 4 years

  4. Time to Onset of 12-week Confirmed Disability Progression (CDP12)

    CDP was defined as a 12-week confirmed increase from baseline in EDSS score of ≥1.0 point in participants with a baseline EDSS score of ≤5.5 or a 12-week CI ≥0.5 points in participants with a baseline EDSS score of \>5.5. The EDSS was used to measure changes in the disability level of participants with MS over time. EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral \[or mental\]) that are rated and then scored as a FSS, and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale where score range from 0 to 5 or 6, and ambulation score that is rated from 0 to 16. These ratings along with observations and assistive devices were then used to determine the total EDSS score. The total EDSS score ranges from 0 (normal) to 10.0 (death) in 0.5-point steps.

    Time frame: Up to approximately 4 years

  5. Time to ≥ 20% Increase in 12-week Confirmed T25FWT

    T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. A 20% change from baseline of the averaged T25FWT was considered clinically meaningful.

    Time frame: Up to approximately 4 years

  6. Annual Rate of Percent Change From Baseline in Total Brain Volume

    Brain volume was measured using magnetic resonance imaging (MRI) scans. Mean difference in annual rate of percent change from baseline in total brain volume between the higher and approved dose of ocrelizumab arms in participants with RMS where no treatment discontinuation nor initiation of alternative MS treatment occurred, are reported.

    Time frame: Up to approximately 4 years

  7. Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT)

    The SDMT is a performance measure that demonstrated sensitivity in detecting the presence of cognitive impairment and changes in cognitive functioning over time \& in response to treatment. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants were asked to pair specific numbers with given geometric figures within 90 seconds. Responses were collected orally. The score is the number of correctly paired items in 90 seconds with a maximum score of 110 and minimum of 0. Higher scores indicate improvement. A four-point change from baseline was considered clinically meaningful.

    Time frame: Up to approximately 4 years

  8. Time to Onset of 24-week Confirmed 8-point Increase in 12-item Multiple Sclerosis Walking Scale (MSWS-12)

    The MSWS-12 was a 12-item self-report measure of the impact of MS on the participant's ability to walk during the past 2 weeks. Each item was scored on a 5-point Likert scale ranging from 1 (not at all) to 5 (extremely likely). Scores were summed and linearly converted to a 0-100 scale with higher scores indicating greater impact of MS on walking ability. An 8-point change was considered clinically meaningful.

    Time frame: Up to approximately 4 years

  9. Fold Change From Baseline in Neurofilament Light (NfL) Chain at Week 48 for Participants Assigned to the Higher Dose Ocrelizumab Group

    NfL is a biomarker of neuroinflammation in CSF. Ratio of change from baseline in NfL at Week 48 for RMS participants where no treatment discontinuation nor initiation of alternative MS treatment occurred within the ocrelizumab higher dose arm has been reported. The results correspond to fold change from baseline (ie ratio of adjusted geometric means at week 48 vs baseline).

    Time frame: Week 48

  10. Fold Change From Baseline in NfL Chain at Week 48 for Participants Assigned to the Approved Dose Ocrelizumab Group

    NfL is a biomarker of neuroinflammation in CSF. Ratio of change from baseline in NfL at Week 48 for RMS participants where no treatment discontinuation nor initiation of alternative MS treatment occurred within the ocrelizumab approved dose arm has been reported. The results correspond to fold change from baseline (ie ratio of adjusted geometric means at week 48 vs baseline).

    Time frame: Week 48

  11. Number of Participants With Adverse Events (AEs)

    AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: From initiation of study drug up to approximately 4 years

  12. Area Under the Serum Concentration-Time Curve (AUC) of Ocrelizumab Over the First Dosing Interval

    Time frame: Day 1 to Week 24

  13. B-cell Levels in Blood

    Time frame: Baseline, Weeks 2, 24, 48, 72, 96, 120, 144, 168, and 192

  14. Percent Change From Baseline in B-cell Levels

    Time frame: Weeks 2, 24, 48, 72, 96, 120, 144, 168, and 192

  15. Percentage of Participants Who Achieved ≤ 5 B-cells/μL of Blood

    Time frame: Baseline, Weeks 2, 24, 48, 72, 96, 120, 144, 168, and 192

  16. Percentage of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab

    Prevalence of ADAs at baseline was defined as the percentage of participants that is ADA positive at baseline. For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer unit (t.u.) greater than the baseline titer result. Percentages have been rounded off.

    Time frame: Baseline up to approximately 4 years

07

Results

Posted Feb 17, 2026

Participant flow

A total of 864 participants with relapsing multiple sclerosis (RMS) took part in the study at 122 investigative sites across 21 countries. The study is still ongoing.

Participant flow — Overall Study
MilestoneOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Started283577
Completed00
Not completed283577
Withdrew: Ongoing in study258517
Withdrew: Adverse event46
Withdrew: Death14
Withdrew: Lost to follow-up12
Withdrew: Reason not specified511
Withdrew: Physician decision08
Withdrew: Withdrawal by subject1429

Outcome measures

PrimaryTime to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)

Time to onset of 12-week cCDP=first occurrence of a 12-week cCDP according to at least 1 of the 3 criteria: 1) CDP=12-week confirmed increase (CI) from baseline (FB) in expanded disability status scale (EDSS) score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 12-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 12-week CI of ≥20% FB in Timed 25-foot Walk Test (T25FWT) score OR 3)12-week CI of ≥ 20% FB in 9-hole Peg Test (9-HPT) score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

Time frame:
Up to approximately 4 years
Reported as:
Median · weeks
Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.5278 · Hazard ratio (hr): 0.93 · 95% CI 0.73 to 1.18
SecondaryTime to Onset of 24-week cCDP (cCDP24)

Time to onset of a 24 week cCDP=first occurrence of a 24-week cCDP according to at least 1 of 3 criteria: 1) CDP=24-week CI from baseline in EDSS score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 24-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 24-week CI of ≥20% FB in T25FWT score OR 3) 24-week CI of ≥ 20% FB in 9-HPT score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

Time frame:
Up to approximately 4 years
Reported as:
Median · weeks
Time to Onset of 24-week cCDP (cCDP24)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 24-week cCDP (cCDP24)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.5273 · Hazard ratio (hr): 0.92 · 95% CI 0.70 to 1.20
SecondaryTime to Onset of 48-week cCDP (cCDP48)

Time to onset of a 48-week cCDP=first occurrence of a 48-week cCDP according to at least 1 of 3 criteria: 1) CDP=48-week CI from baseline in EDSS score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 48-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 48-week CI of ≥20% FB in T25FWT score OR 3) 48-week CI of ≥ 20% FB in 9-HPT score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.

Time frame:
Up to approximately 4 years
Reported as:
Median · weeks
Time to Onset of 48-week cCDP (cCDP48)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 48-week cCDP (cCDP48)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.3663 · Hazard ratio (hr): 0.86 · 95% CI 0.62 to 1.19
SecondaryTime to Onset of cCDP12 Independent of Protocol-defined Relapses (PDR) or Progression Independent of Relapse Activity (PIRA)

Time to onset of 12-week cCDP=first occurrence of a 12-week cCDP according to at least 1 of 3 criteria: 1) CDP=12-week CI from baseline in EDSS score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 12-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 12-week CI of ≥20% FB in T25FWT score OR 3) 12-week CI of ≥ 20% FB in 9-HPT score. EDSS score, T25FWT \& 9-HPT are the same as defined in primary outcome measure. Protocol-defined relapse=occurrence of new or worsening neurological symptoms attributable to MS and immediately preceded by a relatively stable or improving neurological state of at least 30 days. Symptoms persist for at least 24 hours \& accompanied by objective neurological worsening consistent with an increase of one of the following: Half a step (0.5 point) on the EDSS; Two points on one of the functional system scores (FSS) (pyramidal, ambulation, cerebellar, brainstem, sensory, or visual); One point on ≥2 more of the FSS.

Time frame:
Up to approximately 4 years
Reported as:
Median · weeks
Time to Onset of cCDP12 Independent of Protocol-defined Relapses (PDR) or Progression Independent of Relapse Activity (PIRA)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of cCDP12 Independent of Protocol-defined Relapses (PDR) or Progression Independent of Relapse Activity (PIRA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.2632 · Hazard ratio (hr): 0.87 · 95% CI 0.67 to 1.11
SecondaryTime to Onset of 12-week Confirmed Disability Progression (CDP12)

CDP was defined as a 12-week confirmed increase from baseline in EDSS score of ≥1.0 point in participants with a baseline EDSS score of ≤5.5 or a 12-week CI ≥0.5 points in participants with a baseline EDSS score of \>5.5. The EDSS was used to measure changes in the disability level of participants with MS over time. EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral \[or mental\]) that are rated and then scored as a FSS, and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale where score range from 0 to 5 or 6, and ambulation score that is rated from 0 to 16. These ratings along with observations and assistive devices were then used to determine the total EDSS score. The total EDSS score ranges from 0 (normal) to 10.0 (death) in 0.5-point steps.

Time frame:
Up to approximately 4 years
Reported as:
Median · weeks
Time to Onset of 12-week Confirmed Disability Progression (CDP12)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 12-week Confirmed Disability Progression (CDP12)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.5870 · Hazard ratio (hr): 1.10 · 95% CI 0.77 to 1.57
SecondaryTime to ≥ 20% Increase in 12-week Confirmed T25FWT

T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. A 20% change from baseline of the averaged T25FWT was considered clinically meaningful.

Time frame:
Up to approximately 4 years
Reported as:
Median · weeks
Time to ≥ 20% Increase in 12-week Confirmed T25FWT
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to ≥ 20% Increase in 12-week Confirmed T25FWTNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.2687 · Hazard ratio (hr): 0.86 · 95% CI 0.65 to 1.13
SecondaryAnnual Rate of Percent Change From Baseline in Total Brain Volume

Brain volume was measured using magnetic resonance imaging (MRI) scans. Mean difference in annual rate of percent change from baseline in total brain volume between the higher and approved dose of ocrelizumab arms in participants with RMS where no treatment discontinuation nor initiation of alternative MS treatment occurred, are reported.

Time frame:
Up to approximately 4 years
Reported as:
Mean · percent change per year
Annual Rate of Percent Change From Baseline in Total Brain Volume
percent change per yearOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Annual Rate of Percent Change From Baseline in Total Brain Volume-0.397 ± 0.034-0.402 ± 0.031
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Wald Test · p = 0.8740 · Difference in annual rates of change: -0.005 · 95% CI -0.063 to 0.053
SecondaryTime to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT)

The SDMT is a performance measure that demonstrated sensitivity in detecting the presence of cognitive impairment and changes in cognitive functioning over time \& in response to treatment. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants were asked to pair specific numbers with given geometric figures within 90 seconds. Responses were collected orally. The score is the number of correctly paired items in 90 seconds with a maximum score of 110 and minimum of 0. Higher scores indicate improvement. A four-point change from baseline was considered clinically meaningful.

Time frame:
Up to approximately 4 years
Reported as:
Median · weeks
Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 12-week Confirmed 4-point Worsening in Symbol Digit Modality Test (SDMT)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.4927 · Hazard ratio (hr): 0.88 · 95% CI 0.60 to 1.28
SecondaryTime to Onset of 24-week Confirmed 8-point Increase in 12-item Multiple Sclerosis Walking Scale (MSWS-12)

The MSWS-12 was a 12-item self-report measure of the impact of MS on the participant's ability to walk during the past 2 weeks. Each item was scored on a 5-point Likert scale ranging from 1 (not at all) to 5 (extremely likely). Scores were summed and linearly converted to a 0-100 scale with higher scores indicating greater impact of MS on walking ability. An 8-point change was considered clinically meaningful.

Time frame:
Up to approximately 4 years
Reported as:
Median · weeks
Time to Onset of 24-week Confirmed 8-point Increase in 12-item Multiple Sclerosis Walking Scale (MSWS-12)
weeksOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Time to Onset of 24-week Confirmed 8-point Increase in 12-item Multiple Sclerosis Walking Scale (MSWS-12)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ocrelizumab 600 mg vs Ocrelizumab 1200 mg or 1800 mg · Log Rank · p = 0.1263 · Hazard ratio (hr): 0.80 · 95% CI 0.60 to 1.07
SecondaryFold Change From Baseline in Neurofilament Light (NfL) Chain at Week 48 for Participants Assigned to the Higher Dose Ocrelizumab Group

NfL is a biomarker of neuroinflammation in CSF. Ratio of change from baseline in NfL at Week 48 for RMS participants where no treatment discontinuation nor initiation of alternative MS treatment occurred within the ocrelizumab higher dose arm has been reported. The results correspond to fold change from baseline (ie ratio of adjusted geometric means at week 48 vs baseline).

Time frame:
Week 48
Reported as:
Mean · ratio
Fold Change From Baseline in Neurofilament Light (NfL) Chain at Week 48 for Participants Assigned to the Higher Dose Ocrelizumab Group
ratioOcrelizumab 1200 mg or 1800 mg
Fold Change From Baseline in Neurofilament Light (NfL) Chain at Week 48 for Participants Assigned to the Higher Dose Ocrelizumab Group0.63 (0.62 to 0.65)
SecondaryFold Change From Baseline in NfL Chain at Week 48 for Participants Assigned to the Approved Dose Ocrelizumab Group

NfL is a biomarker of neuroinflammation in CSF. Ratio of change from baseline in NfL at Week 48 for RMS participants where no treatment discontinuation nor initiation of alternative MS treatment occurred within the ocrelizumab approved dose arm has been reported. The results correspond to fold change from baseline (ie ratio of adjusted geometric means at week 48 vs baseline).

Time frame:
Week 48
Reported as:
Mean · ratio
Fold Change From Baseline in NfL Chain at Week 48 for Participants Assigned to the Approved Dose Ocrelizumab Group
ratioOcrelizumab 600 mg
Fold Change From Baseline in NfL Chain at Week 48 for Participants Assigned to the Approved Dose Ocrelizumab Group0.63 (0.60 to 0.66)
SecondaryNumber of Participants With Adverse Events (AEs)

AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
From initiation of study drug up to approximately 4 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Number of Participants With Adverse Events (AEs)267552
SecondaryArea Under the Serum Concentration-Time Curve (AUC) of Ocrelizumab Over the First Dosing Interval
Time frame:
Day 1 to Week 24
Reported as:
Geometric mean · micrograms/milliliter*day (µg/mL*day)
Area Under the Serum Concentration-Time Curve (AUC) of Ocrelizumab Over the First Dosing Interval
micrograms/milliliter*day (µg/mL*day)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
600 mg2780 ± 0.291—
1200 mg—6580 ± 0.2
1800 mg—7240 ± 0.288
SecondaryB-cell Levels in Blood
Time frame:
Baseline, Weeks 2, 24, 48, 72, 96, 120, 144, 168, and 192
Reported as:
Mean · cells/microliters (cells/μL)
B-cell Levels in Blood
cells/microliters (cells/μL)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Baseline280.14 ± 174.49270.17 ± 163.88
Week 23.52 ± 23.311.86 ± 11.33
Week 2413.74 ± 30.996.10 ± 24.62
Week 4811.94 ± 26.786.46 ± 25.90
Week 7211.60 ± 33.926.30 ± 29.94
Week 968.16 ± 27.864.60 ± 19.35
Week 1209.36 ± 34.584.57 ± 21.16
Week 14410.51 ± 47.106.05 ± 39.31
Week 16811.41 ± 35.969.19 ± 56.25
Week 1924.25 ± 18.9718.80 ± 108.84
SecondaryPercent Change From Baseline in B-cell Levels
Time frame:
Weeks 2, 24, 48, 72, 96, 120, 144, 168, and 192
Reported as:
Mean · percent change
Percent Change From Baseline in B-cell Levels
percent changeOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Change at Week 2-98.76 ± 5.31-95.67 ± 72.57
Change at Week 24-95.07 ± 9.17-97.25 ± 11.38
Change at Week 48-95.58 ± 8.60-87.26 ± 208.29
Change at Week 72-95.39 ± 11.63-96.94 ± 11.52
Change at Week 96-96.57 ± 11.74-97.68 ± 12.02
Change at Week 120-96.51 ± 11.95-98.01 ± 7.92
Change at Week 144-95.88 ± 19.60-97.60 ± 10.95
Change at Week 168-96.02 ± 12.42-96.61 ± 16.56
Change at Week 192-98.22 ± 6.40-92.64 ± 40.01
SecondaryPercentage of Participants Who Achieved ≤ 5 B-cells/μL of Blood
Time frame:
Baseline, Weeks 2, 24, 48, 72, 96, 120, 144, 168, and 192
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ≤ 5 B-cells/μL of Blood
percentage of participantsOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Baseline00.7
Week 295.395.7
Week 2463.585.3
Week 4864.586.5
Week 7272.486.7
Week 9681.591.0
Week 12081.691.2
Week 14485.692.0
Week 16883.192.9
Week 19290.791.0
SecondaryPercentage of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab

Prevalence of ADAs at baseline was defined as the percentage of participants that is ADA positive at baseline. For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer unit (t.u.) greater than the baseline titer result. Percentages have been rounded off.

Time frame:
Baseline up to approximately 4 years
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab
percentage of participantsOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
Baseline2.62.1
Post-baseline0.40.4

Adverse events

Collected over From initiation of study drug up to approximately 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ocrelizumab 600 mg1/283 (0.4%)34/283 (12%)241/283 (85.2%)
Ocrelizumab 1200 mg or 1800 mg4/577 (0.7%)77/577 (13.3%)502/577 (87%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
COVID-19Infections and infestations1/2839/577
COVID-19 pneumoniaInfections and infestations1/2838/577
PneumoniaInfections and infestations0/2835/577
Inguinal herniaGastrointestinal disorders2/2830/577
DepressionPsychiatric disorders0/2833/577
Atrial fibrillationCardiac disorders1/2830/577
Atrial flutterCardiac disorders1/2830/577
VertigoEar and labyrinth disorders1/2830/577
DrowningGeneral disorders1/2830/577
Autoimmune hepatitisHepatobiliary disorders1/2830/577
Most frequent other events
Showing 10 of 20
Most frequent other events
EventOcrelizumab 600 mgOcrelizumab 1200 mg or 1800 mg
COVID-19Infections and infestations103/283210/577
Infusion related reactionInjury, poisoning and procedural complications79/283198/577
NasopharyngitisInfections and infestations67/283133/577
Upper respiratory tract infectionInfections and infestations58/283107/577
HeadacheNervous system disorders46/28384/577
Urinary tract infectionInfections and infestations30/28374/577
Respiratory tract infectionInfections and infestations28/28351/577
ArthralgiaMusculoskeletal and connective tissue disorders23/28351/577
SinusitisInfections and infestations25/28339/577
Back painMusculoskeletal and connective tissue disorders23/28350/577

Baseline characteristics

Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mgTotal
Mean36.0 ± 9.135.8 ± 8.835.8 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mgTotal
Female180360540
Male103217320
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mgTotal
Hispanic or Latino57101158
Not Hispanic or Latino221466687
Unknown or Not Reported51015
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ocrelizumab 600 mgOcrelizumab 1200 mg or 1800 mgTotal
American Indian or Alaska Native193655
Asian101
Native Hawaiian or Other Pacific Islander011
Black or African American51823
White249511760
More than one race5510
Unknown or Not Reported4610
08

Study locations

121 sites

Showing the first 100 of 121 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hauser SL, Giovannoni G, Montalban X, Oh J, Bar-Or A, Sormani MP, Weber MS, Stoll S, Nicholas JA, Nehrych T, Bonek R, Selmaj K, Maciejowski M, Zecevic D, Raposo C, Owen R, Bonati U, Madjar K, Harfst E, Wang Q, Raievska A, Manfrini M, Schneble HM, Kappos L; MUSETTE and GAVOTTE Study Groups. Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. Lancet. 2026 May 30;407(10544):2180-2194. doi: 10.1016/S0140-6736(26)00147-9. PubMed 42208560 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Dec 2024, 48 months.

Results were first posted in Feb 2026, 1 year 1 month after primary completion.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 48 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

Completion moved twice since we started tracking on Sep 25, 2026: Aug 2028 → Apr 2027, last on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2020
First posted
Sep 10, 2020
StartActual
Nov 26, 2020
Primary completionActual
Dec 19, 2024
CompletionEst.
Apr 1, 2027was Aug 2028
Results first posted
Feb 17, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 Poland, 1 Russia)
  • Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Bada? Klinicznych · Plewiska, Poland
  • SBIH City Clinical Hospital #31 · Saint Petersburg, Russia
Show 1 removed
  • National Center of Social Significant Disease · Saint Petersburg, Russia
Nov 10, 2026
Study completion
Aug 31, 2028→Apr 1, 2027
moved 2 times, Sep 28, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Poland, 1 Russia)
    • Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Bada? Klinicznych · Plewiska, Poland
    • SBIH City Clinical Hospital #31 · Saint Petersburg, Russia
    Show 1 removed
    • National Center of Social Significant Disease · Saint Petersburg, Russia
    Study completion Feb 21, 2028→Apr 1, 2027
    + 1 other change: verification date
  2. Sep 28, 2026
    Study completion Aug 31, 2028→Feb 21, 2028
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04544436
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 10, 2020
Start date
Nov 26, 2020
Primary completion
Dec 19, 2024
Completion
Apr 1, 2027 (estimated)
Results posted
Feb 17, 2026
Last update
Nov 10, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion